Nicolas Nassar

6PUBLICATIONS
33CO-AUTHORS
Molecular targetsHaematologyGene expression (incl. microarray and other genome-wide approaches)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 04, 2026
A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.

|Apr 21, 2026
Unveiling karyoskeletal dynamics in chromatin organization and gene regulation in haematopoietic cell physiology and pathology.

|Mar 19, 2025
Reclassification of ATM Missense Variants of Uncertain Significance by Integrating Results from Systematic Functional Assays into an ACMG Points-Based Framework.

Helmut Hanenberg, Fan Zhang, Nikita Malev

|Jun 01, 2022
Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.

R C Nayak, K H Chang, A K Singh

|Oct 29, 2021
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.

Shailaja Hegde, Anjelika Gasilina, Mark Wunderlich

|Mar 13, 2020
IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models.

Anjelika Gasilina, Gurdat Premnauth, Purujit Gurjar

Pageof 1

Frequent Collaborators

2 joint publications

Benjamin E Mizukawa

2 joint publications

Jose A Cancelas

1 joint publications

R C Nayak

1 joint publications

M Kotliar